NCT03485677 - Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2018

Primary Completion Date

November 20, 2025

Study Completion Date

November 20, 2025

Conditions

Gaucher's Disease Type IGaucher's Disease Type III

Interventions

DRUG

Eliglustat GZ385660

"Pharmaceutical form: Capsule, Liquid~Route of administration: Oral"

DRUG

Imiglucerase GZ437843

"Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous"

Trial Locations (21)

34093

Investigational Site Number : 7920003, Istanbul

35040

Investigational Site Number : 7920002, Izmir

48903

Investigational Site Number : 7240002, Barakaldo

50006

Investigational Site Number : 7240003, Zaragoza

69677

Investigational Site Number : 2500002, Bron

97180

Investigational Site Number : 7520001, Luleå

119049

Investigational Site Number : 6430001, Moscow

119991

Investigational Site Number : 6430004, Moscow

197341

Investigational Site Number : 6430005, Saint Petersburg

634050

Investigational Site Number : 6430002, Tomsk

C1425DUC

Investigational Site Number : 0320001, Capital Federal

T3B 6A8

Investigational Site Number : 1240002, Calgary

V6H 3V4

Investigational Site Number : 1240003, Vancouver

M5G 1X8

Investigational Site Number : 1240001, Toronto

00165

Investigational Site Number : 3800002, Roma

343-8555

Investigational Site Number : 3920002, Koshigaya-shi

105-8471

Investigational Site Number : 3920001, Minato-ku

08950

Investigational Site Number : 7240001, Esplugues de Llobregat

416 85

Investigational Site Number : 7520002, Gothenburg

01300

Investigational Site Number : 7920004, Adana

B4 6NH

Investigational Site Number : 8260002, Birmingham